ArticleACS applied engineering materials2026
Kombucha Bacterial Cellulose Obtained from Tea Fermentation for Biomedical Applications.
Article in ACS applied engineering materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The symbiotic culture of bacteria and yeast (SCOBY) driving kombucha tea fermentation produces a cellulose pellicle with remarkable promise for biomedical applications. Unlike well-studied bacterial cellulose (BC), which is produced by single-strain cultures, the underexplored kombucha-derived bacterial cellulose (KBC) can be produced from agro-industrial waste streams and at low capital cost. This review provides an overview of the great potential of KBC for biomedical applications. First, discussions on the cooperative interactions between bacterial and yeast species within the SCOBY consortium that drive the self-assembled production of cellulose at an air-liquid interface are provided. This is followed by an examination of the influence of carbon source, fermentation conditions, and post-processing on KBC yield, crystallinity, porosity, mechanical properties, and water retention. Physical and chemical modification strategies used to tune KBC behavior are then summarized, including silver (Ag) and gold (Au) functionalization, diisocyanate crosslinking, and incorporation as a nanofiller in biodegradable polymer composites. The applications section focuses on wound dressings and antimicrobial platforms, followed by tissue engineering scaffolds suitable for 3D printing and KBC's role as a drug delivery vehicle. The main barriers to clinical translation are discussed, including limitations in reproducibility linked to undefined SCOBY composition, limited long-term in vivo studies, and the absence of a clear regulatory pathway for functionalized KBC and composites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.